1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
601.59%
Cash & equivalents growing 601.59% while Drug Manufacturers - Specialty & Generic shows decline of -4.00%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-5.55%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-2.61%
Near the Drug Manufacturers - Specialty & Generic median of -2.61% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
73.46%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.28%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.30%. Joel Greenblatt sees a potential liquidity edge if well allocated.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.28%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.42%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
258.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
258.47%
Below half Drug Manufacturers - Specialty & Generic median of -1.60%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
258.47%
Below half Drug Manufacturers - Specialty & Generic median of -0.53%. Joel Greenblatt sees a much lower liability expansion vs. peers.
-2.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.82%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.35%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-2.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-4.94%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-2.28%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.73%. Joel Greenblatt sees more aggressive expansions than peers.
-5.55%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-601.59%
Below half of Drug Manufacturers - Specialty & Generic median 2.45%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
